Ebglyss dosing extended to every eight weeks for atopic dermatitis

What this means

Ebglyss is an injected antibody treatment for moderate-to-severe eczema that blocks interleukin-13, a protein that drives skin inflammation. The FDA approved an extended dosing option allowing injections every 8 weeks instead of every 4 weeks for patients whose eczema is well-controlled. This gives stable patients fewer injections while maintaining treatment effect, with the agency noting "healthcare providers should assess patients periodically to determine if the less frequent dosing regimen remains appropriate.